Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Borderline Resectable Hepatocellular Carcinoma”

4 trials

Showing 4 of 4 results

Testing effectiveness (Phase 2)Study completedNCT05471674
What this trial is testing

Neoadjuvant Anti-PD1 in HCC

Who this might be right for
Hepatocellular CarcinomaHCCLiver Cancer
Dr Tan-to CHEUNG 20
Testing effectiveness (Phase 2)Looking for participantsNCT06904014
What this trial is testing

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

Who this might be right for
HCC
Lei ZHAO 40
Testing effectiveness (Phase 2)UnknownNCT05042336
What this trial is testing

The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC

Who this might be right for
Carrelizumab Plus Lenvatinib Combined With TACEBorderline Resectable Hepatocellular Carcinoma
Sichuan University 49
Early research (Phase 1)Study completedNCT03299946
What this trial is testing

Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)

Who this might be right for
Locally Advanced Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 15

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation